Paige vs Harrison.ai
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Paige
Cancer pathology AI behind the FDA-authorised Paige Prostate, now part...
Visit
|
Harrison.ai
Sydney radiology AI covering up to 124 chest X-ray findings
Visit
|
|
|---|---|---|
| RECATOOLS Score | 8.2 / 10 | 8.2 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Custom | Enterprise |
| Free tier | — | — |
| Paid from | Quoted per deployment; 30-day trial of the diagnostic suites on request | Enterprise contracts quoted on request |
| Has API | ✓ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | In clinical use at hospitals and labs worldwide; training data spans 800+ labs across 45 countries | 3,400+ clinicians at 1,000+ sites across 40+ countries |
| Founded | 2017 | 2018 |
| Maker | Tempus AI | Dr. Aengus Tran (CEO) and Dimitry Tran (co-founder) |
| Verdict | Paige has the strongest regulatory record in AI pathology: a 2021 FDA De Novo authorisation for Paige Prostate, Breakthrough designations, and CE and UKCA marks across its suites. The evidence deserves careful reading, t... |
Harrison.ai offers unusually broad coverage in one product: up to 124 chest X-ray and 130 head CT findings with worklist prioritisation, deployed at more than 1,000 sites and in every public emergency department in Hong... |
| Full review → | Directory listing → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.